18 completed. 18 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 18 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 1 | Completed 1 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome NPI-001, Placebo - Usher Syndromes | Phase 1 / Phase 2 | Completed | Nacuity Pharmaceuticals, Inc. | 49 | 2020-09-03 | 2026-07-01 |
| ADVM-022 Intravitreal Gene Therapy for DME 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept - Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Completed | Adverum Biotechnologies, Inc. | 36 | 2020-05-28 | 2025-07-10 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome Sodium Valproate 200Mg E/C Tablet, Sodium Valproate matched placebo - Wolfram Syndrome | Phase 2 | Completed | University of Birmingham | 63 | 2018-12-28 | 2026-05-05 |
| A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 21 | 2017-01-01 | 2024-03-13 |
| Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. AZD4017, Placebo - Idiopathic Intracranial Hypertension | Phase 2 | Completed | University of Birmingham | 31 | 2014-04-25 | 2021-10-27 |
| Revacept in Symptomatic Carotid Stenosis Revacept, Placebo - Carotid Stenosis, Atherosclerosis | Phase 2 | Completed | AdvanceCor GmbH | 158 | 2013-03-08 | 2021-01-28 |
| Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study verum tDCS, sham tDCS, VRT - Hemianopia, Stroke | Phase 1 / Phase 2 | Completed | University of Magdeburg | 19 | 2013-03-01 | 2016-03-09 |
| Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study tDCS, Standard rehabilitation - Hemianopia, Stroke | Phase 1 / Phase 2 | Completed | University of Magdeburg | 14 | 2013-01-01 | 2016-10-17 |
| Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) LFG316, Sham, LFG316 Lower dose - Geographic Atrophy, Age-related Macular Degeneration | Phase 2 | Completed | Novartis Pharmaceuticals | 158 | 2012-01-25 | 2021-01-05 |
| Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa NT-501, Sham - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Completed | Neurotech Pharmaceuticals | 22 | 2012-01-01 | 2023-02-14 |
| Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions Verum stimulation, Placebo stimulation - Complete Hemianopia, Incomplete Hemianopia | Phase 2 | Completed | University of Magdeburg | 32 | 2011-03-01 | 2019-07-05 |
| Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects melatonin (Circadin), placebo - Non-24 Hour Sleep-Wake Disorder, Blindness | Phase 2 | Completed | Neurim Pharmaceuticals Ltd. | 13 | 2006-02-01 | 2009-09-09 |
| Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Rituximab - Ocular Cicatricial Pemphigoid | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 3 | 2006-01-01 | 2026-05-04 |
| Restoration vs. Compensation in Neurovisual Rehabilitation of Visual Field Defects Vision Restoration Training (VRT), Vision Exploration Training (VET) - Hemianopia, Brain Injuries, Traumatic | Phase 2 | Completed | University of Magdeburg | 86 | 2003-01-01 | 2019-08-02 |
| Evaluation of Eye Movement Tracking Systems for Visual Rehabilitation Visual - Blindness | Phase 2 | Completed | US Department of Veterans Affairs | 100 | 2000-01-01 | 2009-01-21 |
| The Impact of Rehabilitation on Quality of Life in Visually Impaired Blindness - Blindness | Phase 2 | Completed | US Department of Veterans Affairs | 300 | 1999-04-01 | 2015-06-26 |
| Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity Supplemental Oxygen Management, Conventional Oxygen Management - Infant, Newborn, Infant, Low Birth Weight | Phase 2 / Phase 3 | Completed | NICHD Neonatal Research Network | 649 | 1994-02-01 | 2015-06-08 |
Hemianopsia (4) · Stroke (4) · Usher Syndromes (3) · Brain Injuries, Traumatic (2) · Eye Diseases (2) · Retinal Diseases (2) · Retinitis Pigmentosa (2) · Wolfram Syndrome (2) · Amaurosis Fugax (1) · Ataxia (1) · Atherosclerosis (1) · Carotid Stenosis (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1)
Nervous System Diseases (18) · Neurologic Manifestations (18) · Sensation Disorders (18) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (17) · Vision Disorders (17) · Eye Diseases (16) · Brain Diseases (6) · Central Nervous System Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Ear Diseases (6) · Hearing Disorders (6) · Otorhinolaryngologic Diseases (6) · Abnormalities, Multiple (5)
salicylhydroxamic acid (2) · 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid (1) · Ciliary Neurotrophic Factor (1) · Control Groups (1) · Dantrolene (1) · Electroconvulsive Therapy (1) · Intravitreal Injections (1) · Melatonin (1) · Revacept (1) · Rituximab (1) · Transcranial Direct Current Stimulation (1) · Valproic Acid (1) · aflibercept (1)
University of Magdeburg (4) · US Department of Veterans Affairs (2) · University of Birmingham (2) · AdvanceCor GmbH (1) · Adverum Biotechnologies, Inc. (1) · NICHD Neonatal Research Network (1) · Nacuity Pharmaceuticals, Inc. (1) · Neurim Pharmaceuticals Ltd. (1) · Neurotech Pharmaceuticals (1) · Novartis Pharmaceuticals (1) · ProQR Therapeutics (1) · University of Alabama at Birmingham (1) · Washington University School of Medicine (1)
United States (10) · Germany (5) · United Kingdom (3) · Austria (2) · France (2) · Australia (1) · Canada (1) · Poland (1) · Puerto Rico (1) · Spain (1)
John Fryer, Ph.D., Asst. Director (2) · Nancy Rocheleau, Program Analyst (2) · Alan Lankford, PhD (1) · Alan R. Spitzer, MD (1) · Alexandra Sinclair, MbChb PhD (1) · Barbara J. Stoll, MD (1) · Bernhard A Sabel, Ph.D. (1) · Bernhard A Sabel, Prof. Dr. (1) · Beverly S. Brozanski, MD (1) · Charles C. Barr, MD (1) · Craig A Elmets (1) · Cynthia Cole, MD (1) · Dale L. Phelps, MD (1) · David Easa, MD (1) · David K. Stevenson, MD (1)
PMID 10654946, PMID 24504128, PMID 25678831, PMID 28082176, PMID 28923789, PMID 31215818, PMID 33098644, PMID 34185708, PMID 34219679, PMID 35695006, PMID 36240084, PMID 37314061, PMID 37418643, PMID 37740611, PMID 40010822
2018 (1), M01RR000054 (1), M01RR000070 (1), R21DK113487 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1), U10HD027871 (1), U10HD027880 (1), U10HD027904 (1), U10HD040689 (1)